Candel Therapeutics shares 20-month follow-up data for its prostate cancer candidate ahead of FDA filing

Candel Therapeutics announced that it has completed a long-term follow‑up study of patients treated with its prostate cancer drug. The data extend to about 20 months after treatment and are intended to strengthen the company’s filing with the U.S. Food and Drug Administration later this year.

The company’s chief executive, Paul Peter Tak, said the results could bolster the case for marketing approval, although specific efficacy numbers were not disclosed in the brief report.

The announcement was made on May 15, 2026, and appears in a short news release that encourages readers to sign up for full access to the article. No additional details about safety, side effects, or comparative performance were provided.

If the data are viewed positively by regulators, they could accelerate the timeline for the drug’s potential launch, which would be of interest to investors and other stakeholders in the oncology space.